ストックスクリーナーアプリを入手
50.60
0.10%
0.07
前日終値:
$50.53
開ける：
$50.82
24時間の取引高:
2.32M
Relative Volume:
0.45
時価総額：
$101.54B
収益：
$43.93B
当期純損益:
$8.53B
株価収益率:
13.23
EPS:
3.824
ネットキャッシュフロー:
$5.74B
1週間 パフォーマンス:
-3.31%
1か月 パフォーマンス:
-9.42%
6か月 パフォーマンス:
+8.47%
1年 パフォーマンス:
+36.08%
1日の値動き範囲:
$50.41
$50.82
1週間の範囲:
$50.02
$52.23
52週間の値動き範囲:
$35.45
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.58 | 101.44B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
976.80 | 880.19B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
222.12 | 540.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
202.64 | 362.65B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
182.47 | 286.78B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
145.50 | 283.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-11-25 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-06-03 | ダウングレード | Berenberg | Buy → Hold |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-11-12 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-07-08 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-30 | 開始されました | Goldman | Neutral |
| 2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2024-01-03 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 再開されました | Goldman | Buy |
| 2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-11 | ダウングレード | UBS | Neutral → Sell |
| 2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 再開されました | Citigroup | Neutral |
| 2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Hold |
| 2020-11-02 | アップグレード | Liberum | Hold → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
| 2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 開始されました | SVB Leerink | Outperform |
| 2019-11-21 | アップグレード | UBS | Neutral → Buy |
| 2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 再開されました | Citigroup | Neutral |
| 2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
| 2019-08-13 | 再開されました | JP Morgan | Neutral |
| 2019-06-17 | 再開されました | Morgan Stanley | Underweight |
| 2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
| 2019-02-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-08-30 | ダウングレード | Liberum | Buy → Hold |
| 2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
GSK Stock Quote Price and Forecast - CNN
Major holder in GSK (NYSE: GSK) reports 4.93% of voting rights - Stock Titan
GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK) - MarketBeat
GSK Stock Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor Intelligence - GlobeNewswire Inc.
GSK Forecast, Price Target & Analyst Ratings | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK out-licenses rights for rare liver disease drug to Alfasigma - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
GSK Fundamental Analysis & Valuation | Fair Value & Financial Strength | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
Farther Finance Advisors LLC Grows Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Miller Howard Investments Inc. NY - MarketBeat
GSK plc (ADR) stock (GB0009252882): Why Google Discover changes matter more now - AD HOC NEWS
GSK PLC Stock Operating Data - GuruFocus
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK plc (ADR) stock (GB0009252882): Why its vaccines and specialty medicines strategy is suddenly wo - AD HOC NEWS
GSK Reports Promising Early Data For Experimental Cancer Drug - Sahm
GSK PLC Sponsored ADR $GSK Shares Acquired by Prime Capital Investment Advisors LLC - MarketBeat
Douglas Lane & Associates LLC Cuts Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Singapore
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo! Finance Canada
GSK plc (ADR) Stock: ViiV Healthcare Ownership Restructured as Pfizer Exits, Strengthening GSK's HIV - AD HOC NEWS
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK plc (ADR) stock surges on FDA approval for Lynavoy as pipeline momentum builds for 2026 - AD HOC NEWS
GSK's Q4 earnings & sales beat estimates, stock up on '26 outlook - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Update - MarketBeat
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Sahm
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
GSK (NYSE: GSK) files 2025 Form 20-F with audited 2025 financial statements - Stock Titan
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
0.55%
1.93%
大文字化:
|
ボリューム (24 時間):